OMH Osmetech

 

TIDMOMH 
 
RNS Number : 6285M 
Osmetech PLC 
27 May 2010 
 

 
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR 
FROM THE UNITED STATES OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE 
A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. 
THIS ANNOUNCEMENT IS MADE IN ACCORDANCE WITH THE REQUIREMENTS OF THE AIM RULES 
FOR COMPANIES. 
 
                                  Osmetech plc 
                  Scheme of Arrangement update: Revised timing 
Further to the announcement by Osmetech plc yesterday, 26 May 2010 regarding the 
timing of the Court Hearing in relation to the Scheme and the closing of the 
GenMark Fundraising, the Company announces that there has been a further delay 
to the closing of the Genmark Fundraising and that accordingly the suspension of 
trading in Osmetech Shares will not be taking place today and the Court Hearing 
to sanction the Scheme due to take to place today is expected to be adjourned. 
 
The Company anticipates that there will be a further short delay to the 
timetable, and the Company expects to announce a revised timetable later today. 
 
 
Terms defined in the Scheme Circular shall have the same meaning(s) when used in 
this announcement. 
 
Contacts 
For further information contact: 
Osmetech plc 
Steven Kemper, Chief Financial Officer - +1 626 463 2004 
Jon Faiz Kayyem, Chief Executive Officer - +1 626 463 2000 
 
Canaccord Genuity Limited 
(Nominated Advisor) 
020 7050 6500 
Robert Finlay 
Henry Fitzgerald-O'Connor 
 
THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY 
ANY SECURITIES OF GENMARK OR OSMETECH, NOR SHALL IT FORM THE BASIS OF, OR BE 
RELIED UPON IN CONNECTION WITH ANY CONTRACT FOR SUCH PURCHASE OR SUBSCRIPTION. 
THE GENMARK SHARES TO BE ISSUED PURSUANT TO THE SCHEME WILL ONLY BE ISSUED TO 
OSMETECH SHAREHOLDERS IN ACCORDANCE WITH THE SCHEME AND THE SCHEME CIRCULAR. 
the GenMark Shares to be issued pursuant to the Scheme will not be registered 
with the SEC under the Securities Act, but will be issued in reliance upon an 
exemption from the registration requirements. 
A REGISTRATION STATEMENT RELATING TO THE ISSUANCE OF GENMARK SHARES IN THE 
GENMARK FUNDRAISING HAS BEEN FILED WITH THE SEC.  OFFERS OF THESE SECURITIES MAY 
BE MADE ONLY BY MEANS OF A PROSPECTUS MEETING THE APPLICABLE REQUIREMENTS OF 
UNITED STATES LAWS AND REGULATIONS AND THE LAWS AND REGULATIONS OF ANY OTHER 
JURISDICTION IN WHICH SUCH SECURITIES MAY BE LAWFULLY OFFERED FOR SALE. 
Apart from the responsibilities and liabilities, if any, which may be imposed on 
Canaccord Genuity Limited by the FSMA or the regulatory regime established 
thereunder, Canaccord Genuity Limited does not accept any responsibility 
whatsoever for the contents of this announcement or for any statement made or 
purported to be made by it, or on its behalf, in connection with Osmetech, 
GenMark, the Osmetech Shares, the GenMark Shares or the Proposal.  Canaccord 
Genuity Limited accordingly disclaims all and any liability whether arising in 
tort, contract or otherwise (save as referred to above) which it might otherwise 
have in respect of this statement or any such statement. 
Canaccord Genuity Limited, which is authorised and regulated in the United 
Kingdom by the FSA, is acting exclusively for Osmetech and GenMark and no one 
else in connection with the Proposal and will not be responsible to anyone other 
than Osmetech and GenMark for providing the protections afforded to clients of 
Canaccord Genuity Limited nor for providing advice in relation to the Proposal 
or the contents of this announcement, or any matter referred to herein. 
Statements in this announcement regarding the Scheme, including expectations 
with respect to the Scheme and the timetable for completing the Scheme, the 
ability to list the GenMark Shares on the NASDAQ Global Market and complete the 
GenMark Fundraising, future financial operating results, potential benefits of 
the Scheme, and future opportunities for Osmetech or GenMark as well as any 
other statements about the future expectations, beliefs, goals, plans or 
prospects of the management of Osmetech or GenMark constitute "forward-looking" 
statements.  Any statements that are not statements of historical fact 
(including statements containing the words "believe", "plan", "anticipate", 
"expect", "estimate", and similar expressions) should also be considered to be 
forward-looking in nature.  There are a number of important factors that could 
cause actual results or events to differ materially from those indicated by such 
forward-looking statements, including not obtaining the necessary approvals to 
complete the Scheme on a timely basis, or at all, inability to complete the 
GenMark Fundraising on favourable terms, or at all, decreases in demand for 
Osmetech's products and other factors described in Osmetech's Annual Report for 
the year ended 31 December 2008.  Osmetech disclaims any intention or obligation 
to update any forward-looking statements as a result of developments occurring 
after the date of this announcement.  Osmetech Shareholders are cautioned not to 
place undue weight on these forward-looking statements. Actual results may 
differ materially from those anticipated in such forward-looking statements even 
if experience or future changes make it clear that any projected results 
expressed or implied therein may not be realised. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 SOASELSMWFSSESI 
 

Osmetech (LSE:OMH)
Historical Stock Chart
From Nov 2024 to Dec 2024

Osmetech (LSE:OMH)
Historical Stock Chart
From Dec 2023 to Dec 2024